Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 9/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.42 |
| ▸ | DRD2 | P14416 | 7/20 | 0.33 |
| ▸ | HTR2A | P28223 | 7/20 | 0.33 |
| ▸ | DRD3 | P35462 | 7/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CCR3 | P51677 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30828944 | 1.00 | CHRM4 (0.54) | CHRM4CHRM1CHRM2DRD2HTR2A | |
| SCHEMBL23212969 | 1.00 | CHRM4 (0.54) | CHRM4CHRM1CHRM2DRD2HTR2A | |
| SCHEMBL23213668 | 0.88 | CHRM4 (0.61) | CHRM4CHRM1CHRM2ALDH1A1CHRM5 | |
| SCHEMBL23213670 | 0.88 | CHRM4 (0.61) | CHRM4CHRM1CHRM2ALDH1A1CHRM5 | |
| SCHEMBL23213272 | 0.87 | CHRM4 (0.53) | CHRM4CHRM1CHRM2DRD2HTR2A | |
| SCHEMBL23210089 | 0.84 | CHRM4 (0.57) | CHRM4CHRM1CHRM2DRD2HTR2A | |
| SCHEMBL23210087 | 0.84 | CHRM4 (0.57) | CHRM4CHRM1CHRM2DRD2HTR2A | |
| SCHEMBL23229981 | 0.84 | CHRM4 (0.42) | CHRM4CHRM1CHRM2DRD2HTR2A | |
| SCHEMBL23295190 | 0.84 | CHRM4 (0.42) | CHRM4CHRM1CHRM2DRD2HTR2A | |
| SCHEMBL29871408 | 0.83 | CHRM4 (0.49) | CHRM4CHRM1CHRM2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140959-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS AG (CH) | 2024-05-02 | — | — | US | disclosed |
| US-11820778-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | NOVARTIS AG (CH) | 2023-11-21 | — | — | US | disclosed |
| US-20220411435-A1 | 2-AZASPIRO[3,4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-12-29 | — | — | US | disclosed |
| US-20210130365-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2021-05-06 | — | — | US | disclosed |
| WO-2021070091-A1 | 5-OXA-2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS AG (CH) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140959-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | CHRM4 4/4885CHRM1 2/4885CHRM2 1/4885 |
| US-20210130365-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | CHRM4 4/4885CHRM1 2/4885CHRM2 1/4885 |
| US-20220411435-A1 | 2-AZASPIRO[3,4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | CHRM4 4/4885CHRM1 2/4885CHRM2 1/4885 |
| US-11820778-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | CHRM2, CHRM1, CHRM3 | CHRM4 4/4885CHRM1 2/4885CHRM2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.